uniQure (NASDAQ:QURE) Director Sells 11,685 Shares

by · The Markets Daily

uniQure N.V. (NASDAQ:QURE – Get Free Report) Director Madhavan Balachandran sold 11,685 shares of the stock in a transaction on Wednesday, June 17th. The stock was sold at an average price of $45.06, for a total transaction of $526,526.10. Following the transaction, the director directly owned 43,254 shares in the company, valued at approximately $1,949,025.24. This represents a 21.27% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Madhavan Balachandran also recently made the following trade(s):

  • On Monday, June 15th, Madhavan Balachandran sold 10,000 shares of uniQure stock. The shares were sold at an average price of $27.85, for a total value of $278,500.00.
  • On Thursday, June 11th, Madhavan Balachandran sold 1,993 shares of uniQure stock. The shares were sold at an average price of $27.06, for a total value of $53,930.58.

uniQure Stock Performance

QURE opened at $46.29 on Monday. The company has a current ratio of 10.40, a quick ratio of 10.40 and a debt-to-equity ratio of 0.33. uniQure N.V. has a 1-year low of $8.73 and a 1-year high of $71.50. The company has a market cap of $2.92 billion, a price-to-earnings ratio of -13.30 and a beta of 0.98. The company’s fifty day moving average price is $24.74 and its two-hundred day moving average price is $22.17.

uniQure (NASDAQ:QURE – Get Free Report) last released its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported ($0.85) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.88) by $0.03. uniQure had a negative return on equity of 145.81% and a negative net margin of 1,154.42%.The business had revenue of $3.56 million during the quarter, compared to the consensus estimate of $5.21 million. On average, analysts expect that uniQure N.V. will post -3.64 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

QURE has been the subject of a number of recent analyst reports. TD Cowen restated a “buy” rating on shares of uniQure in a research note on Tuesday, March 3rd. Stifel Nicolaus set a $28.00 target price on uniQure in a research report on Tuesday, May 5th. HC Wainwright reaffirmed a “buy” rating on shares of uniQure in a research note on Thursday. Mizuho upgraded uniQure from a “neutral” rating to an “outperform” rating and upped their target price for the stock from $12.00 to $35.00 in a research note on Wednesday, March 11th. Finally, Leerink Partners lifted their price objective on shares of uniQure from $36.00 to $70.00 and gave the stock an “outperform” rating in a report on Thursday. Twelve analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $58.92.

Read Our Latest Stock Report on QURE

Institutional Investors Weigh In On uniQure

Large investors have recently made changes to their positions in the business. Vanguard Group Inc. boosted its stake in uniQure by 15.7% in the 3rd quarter. Vanguard Group Inc. now owns 1,125,108 shares of the biotechnology company’s stock worth $65,673,000 after purchasing an additional 152,417 shares in the last quarter. Aberdeen Group plc boosted its stake in shares of uniQure by 25.1% in the 4th quarter. Aberdeen Group plc now owns 3,678,640 shares of the biotechnology company’s stock worth $88,030,000 after buying an additional 738,897 shares during the last quarter. Quinn Opportunity Partners LLC bought a new stake in shares of uniQure during the 3rd quarter valued at about $6,281,000. Farallon Capital Management LLC increased its holdings in uniQure by 3,935.7% during the third quarter. Farallon Capital Management LLC now owns 565,000 shares of the biotechnology company’s stock valued at $32,979,000 after buying an additional 551,000 shares during the last quarter. Finally, Boone Capital Management LLC purchased a new position in uniQure during the third quarter valued at $8,599,000. 78.83% of the stock is currently owned by institutional investors.

uniQure Company Profile

(Get Free Report)

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.

See Also